This compound is primarily utilized in pharmaceutical research and development, particularly in the synthesis of active pharmaceutical ingredients (APIs) targeting neurological and psychiatric disorders. Its structure, featuring a fluorinated dihydrobenzodioxin moiety, makes it a valuable intermediate for designing drugs with enhanced selectivity and efficacy. It is often explored in the development of serotonin receptor modulators, which are critical in treating conditions such as depression, anxiety, and schizophrenia. Additionally, its chiral center allows for the creation of enantiomerically pure compounds, which can improve therapeutic outcomes by minimizing off-target effects. Researchers also investigate its potential in cancer therapy, leveraging its ability to interact with specific biological pathways.